Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27634200 | 0.81 | KCNH2 (0.47) | KCNH2HCAR2HCAR3P2RX7 | |
| SCHEMBL25436967 | 0.77 | GAA (0.37) | KCNH2 | |
| SCHEMBL27538531 | 0.76 | KCNH2 (0.44) | KCNH2HCAR2HCAR3P2RX7 | |
| SCHEMBL17164752 | 0.68 | KCNH2 (0.37) | KCNH2HCAR2HCAR3P2RX7 | |
| SCHEMBL8943452 | 0.68 | KCNH2 (0.37) | KCNH2HCAR2HCAR3P2RX7 | |
| SCHEMBL5752138 | 0.68 | KCNH2 (0.37) | KCNH2HCAR2HCAR3P2RX7 | |
| SCHEMBL4109180 | 0.67 | KCNH2 (0.75) | KCNH2 | |
| SCHEMBL5898715 | 0.65 | KCNH2 (0.35) | KCNH2HCAR2HCAR3 | |
| SCHEMBL16657588 | 0.65 | KCNH2 (0.35) | KCNH2HCAR2HCAR3 | |
| Hydrochloric Acid SCHEMBL5616504 | 0.64 | KCNH2 (0.34) | KCNH2HCAR2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | disclosed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105909-A1 | Compounds useful in therapy | GNRHR, OPRK1, CBR3 | KCNH2 378/4885HCAR2 381/4885HCAR3 63/4885 |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | CBR3, GNRHR, RXFP3 | KCNH2 262/4885HCAR2 643/4885HCAR3 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.